New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheimer’s disease (AD) ...

Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented an analysis from the Phase 2 ...

A study shows that about a quarter of people with clinically diagnosed mild or moderate Alzheimer’s disease (AD) have only minimal β-amyloid (Aβ) deposition on autopsy. And nearly half of patients ...

Dr Ray O’Connor takes a look at the latest clinical studies on dementia, including its diagnosis and management ...

Dementia is a group of disorders that gradually impair memory, thinking and daily functioning. Alzheimer's disease (AD), the most common form of dementia, affects about 7.2 million Americans aged 65 ...

Rising diagnoses of young onset dementia highlight the need for early recognition and timely evaluation of a condition that disrupts patients’ careers, families, and financial stability.

New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheimer’s disease (AD) co-pathology — experienced greater clinical benefit wit ...